Ionis Pharmaceuticals (IONS) PT Lowered to $95 at BMO Capital, Lowers Spinraza Estimates
Tweet Send to a Friend
BMO Capital analyst Do Kim lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $95.00 (from $96.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
